NO20013013D0 - <Alpha> v <beta> 6-integrin - Google Patents

<Alpha> v <beta> 6-integrin

Info

Publication number
NO20013013D0
NO20013013D0 NO20013013A NO20013013A NO20013013D0 NO 20013013 D0 NO20013013 D0 NO 20013013D0 NO 20013013 A NO20013013 A NO 20013013A NO 20013013 A NO20013013 A NO 20013013A NO 20013013 D0 NO20013013 D0 NO 20013013D0
Authority
NO
Norway
Prior art keywords
integrin
beta
alpha
Prior art date
Application number
NO20013013A
Other languages
Norwegian (no)
Other versions
NO20013013L (en
Inventor
Beate Diefenbach
Alfred Jonczyk
Sabine Kraft
Ray Mehta
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO20013013L publication Critical patent/NO20013013L/en
Publication of NO20013013D0 publication Critical patent/NO20013013D0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
NO20013013A 1998-12-19 2001-06-18 <Alpha> v <beta> 6-integrin NO20013013D0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19858857 1998-12-19
PCT/EP1999/009842 WO2000037487A1 (en) 1998-12-19 1999-12-11 αvβ6 INTEGRIN INHIBITORS

Publications (2)

Publication Number Publication Date
NO20013013L NO20013013L (en) 2001-06-18
NO20013013D0 true NO20013013D0 (en) 2001-06-18

Family

ID=7891834

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013013A NO20013013D0 (en) 1998-12-19 2001-06-18 <Alpha> v <beta> 6-integrin

Country Status (10)

Country Link
EP (1) EP1140989A1 (en)
JP (1) JP2002533064A (en)
CN (1) CN1335853A (en)
AR (1) AR022395A1 (en)
BR (1) BR9916323A (en)
CA (1) CA2355874A1 (en)
CZ (1) CZ20012212A3 (en)
NO (1) NO20013013D0 (en)
WO (1) WO2000037487A1 (en)
ZA (1) ZA200105929B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19929410A1 (en) * 1999-06-26 2000-12-28 Merck Patent Gmbh New octapepide compounds as alpha v beta 6 integrin inhibitors useful for treating and diagnosing heart disease, tumors, osteoporosis, fibrosis, inflammation, infection and psoriasis
DE19933173A1 (en) * 1999-07-15 2001-01-18 Merck Patent Gmbh Cyclic peptide derivatives as inhibitors of the integrin alpha¶v¶beta¶6¶
EP2287198A3 (en) 2002-03-13 2011-05-25 Biogen Idec MA Inc. Anti-alpha V beta 6 antibodies
DE502004007051D1 (en) * 2003-02-06 2008-06-19 Merck Patent Gmbh PEPTIDIC SULFONAMIDE
CN102875681A (en) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 Anti-alpha v beta 6 antibodies and uses thereof
GB0520068D0 (en) 2005-10-03 2005-11-09 Cancer Res Technology av peptide ligand
US7927590B2 (en) 2006-07-10 2011-04-19 Biogen Idec Ma Inc. Compositions and methods for inhibiting growth of smad4-deficient cancers
CN103524619B (en) 2006-08-03 2016-10-05 阿斯利康(瑞典)有限公司 Antibody and application thereof for α V β 6
AU2007354317A1 (en) * 2006-10-19 2008-12-04 Biogen Idec Ma Inc. Treatment and prevention of chronic asthma using antagonists of integrin alphaVbeta6
WO2009093251A2 (en) * 2008-01-24 2009-07-30 Gavish-Galilee Bio Applications Ltd Reovirus vaccine based on sigma c protein sequence
CN104470943B (en) * 2012-07-03 2017-07-14 一洋药品株式会社 New peptide and application thereof
US10035859B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
WO2014143739A2 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
MA52117A (en) 2017-02-28 2022-04-06 Morphic Therapeutic Inc INHIBITORS OF INTEGRIN (ALPHA-V) (BETA-6)
MX2019010267A (en) 2017-02-28 2020-02-05 Morphic Therapeutic Inc Inhibitors of (alpha-v)(beta-6) integrin.
US20200071322A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibiting (alpha-v)(beta-6) integrin

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ219515A (en) * 1987-02-10 1989-09-27 Wellcome Found Fusion proteins comprising influenza virus ha and a nonnatural antigenic epitope

Also Published As

Publication number Publication date
CA2355874A1 (en) 2000-06-29
WO2000037487A1 (en) 2000-06-29
BR9916323A (en) 2001-10-30
NO20013013L (en) 2001-06-18
CN1335853A (en) 2002-02-13
EP1140989A1 (en) 2001-10-10
ZA200105929B (en) 2003-03-18
CZ20012212A3 (en) 2001-09-12
WO2000037487A8 (en) 2001-03-29
JP2002533064A (en) 2002-10-08
AR022395A1 (en) 2002-09-04

Similar Documents

Publication Publication Date Title
NO20006268D0 (en) &lt;Beta&gt; karbolinforbindelser
ID25977A (en) DIAPON ONCE USE
ID24555A (en) DIAPON ONCE USE
ID26301A (en) PITOT-STATIS TUBES
DE69827672D1 (en) TELESCOPIC-LIKE INTRAORAL ELEMENT
IS5699A (en) New use
ID26162A (en) BENZILBIFENIL BIOSIDA DESIGNS
ID23761A (en) SUBSTITUTED TRISICLIC
NO992667D0 (en) Human &lt;beta&gt; 2-integrin &lt;alfa&gt; subunit
DE69902762D1 (en) RISER-SPAN ARRANGEMENT
NO20013013D0 (en) &lt;Alpha&gt; v &lt;beta&gt; 6-integrin
NO971248D0 (en) 5 &lt;alpha&gt; -reduktaseinhibitorer
ID23219A (en) SUBSTITUTED TRISICLIC
NO20014010D0 (en) &lt;Beta&gt; -alaninderivater
DE59901977D1 (en) Analog-to-digital converter
NO20020885D0 (en) &lt;Alpha&gt; v &lt;beta&gt; 3-integrin
FI980759A0 (en) Taetningskonstruktion Foer suglaodan i en sugvals
DE59912188D1 (en) SUBSTITUTED PHENYLURACILE
ATE303996T1 (en) SUBSTITUTED ACYLAMINOPHENYL URACILES
PT1076660E (en) (4-BROMOPYRAZOL-3-YL) -BZZAZOLES
NO980270D0 (en) Trekka scheme
NO20010280L (en) &lt;Alfa&gt; -aminosyrefenylesterderivater
FI980743A0 (en) Gap-valsformare i en pappersmaskin
DE29813237U1 (en) Weisswurst dish
SE9804280D0 (en) Crane-related attachment

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application